Trintellix And Rem Sleep: What's The Connection?

Trintellix (generic name vortioxetine) is a multimodal antidepressant that acts as a serotonin modulator and stimulator. It is a serotonin transporter (SERT) inhibitor and a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, a 5-HT1B receptor partial agonist, and a 5-HT1A receptor agonist. Antidepressants often disrupt sleep, but vortioxetine has been found to have fewer incidences of sleep-related adverse events reported in depressed patients.

In a study comparing vortioxetine to paroxetine, a selective serotonin reuptake inhibitor (SSRI), vortioxetine was found to have less of an effect on REM sleep. In the study, vortioxetine decreased the duration of REM sleep during the day, whereas paroxetine produced a decrease in REM sleep throughout the day on all days. Another study found that vortioxetine improved subjective sleep quality and continuity in depressed patients.

Overall, vortioxetine has been found to have a less intense REM-suppressing effect than other antidepressants, indicating its different pharmacological profile.

Vortioxetine is a multimodal antidepressant that acts on serotonin (5-HT) transporter (SERT) inhibition, 5-HT3, 5-HT7 and 5-HT1D receptor antagonism, 5-HT1B receptor partial agonism, and 5-HT1A receptor agonism

Vortioxetine has been found to have fewer incidences of sleep-related adverse events reported in depressed patients when compared to other antidepressants. It has been found to have a different effect on REM sleep than paroxetine, another antidepressant. Vortioxetine has been found to have a REM-suppressing effect, which is less pronounced than that of other antidepressants. This effect is attributed to 5-HT3 receptor antagonism and higher affinity to this receptor. Vortioxetine has also been found to have fewer effects on sleep fragmentation than other antidepressants.

Vortioxetine has fewer incidences of sleep-related adverse events reported in depressed patients

Vortioxetine is a multimodal antidepressant that acts as a serotonin (5-HT) transporter (SERT) inhibitor, 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, and 5-HT1A receptor agonist. Antidepressants often disrupt sleep, but vortioxetine has been found to have fewer incidences of sleep-related adverse events reported in depressed patients.

In a study comparing vortioxetine to paroxetine, vortioxetine was found to have less of an effect on REM sleep. In the study, vortioxetine decreased the duration of REM sleep throughout the day on the first day of the study, while paroxetine produced a decrease in REM sleep throughout the day on all days. After repeated administration, vortioxetine yielded normal sleep-wake rhythms, while paroxetine continued to suppress REM sleep.

Another study found that vortioxetine may improve sleep quality in depressed patients with insomnia. In the study, patients with major depressive disorder and insomnia were treated with vortioxetine. The Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Beck Depression Inventory were all used to evaluate patients before and after treatment. The Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale scores decreased significantly between follow-up and baseline, indicating an improvement in sleep quality and daytime sleepiness. The Beck Depression Inventory score also decreased between follow-up and baseline.

A third study evaluated the effects of vortioxetine on sleep architecture in adolescents with major depressive disorder. The study found that vortioxetine had a dose-dependent REM-suppressing effect, indicating altered sleep architecture as a potential result of vortioxetine treatment.

Vortioxetine has a different pharmacological profile to paroxetine, an SSRI

Vortioxetine, a multimodal antidepressant, has a different pharmacological profile to paroxetine, an SSRI. Vortioxetine acts as a serotonin modulator and stimulator, whereas paroxetine is a selective serotonin reuptake inhibitor. Vortioxetine inhibits serotonin transporter (SERT) and acts as an agonist of the 5-HT1A receptor, partial agonist of the 5-HT1B receptor, and antagonist of the 5-HT1D, 5-HT3, and 5-HT7 receptors. Paroxetine, on the other hand, acts solely as an SSRI.

Vortioxetine has a different mechanism of action to paroxetine, which is reflected in its pharmacodynamic profile. Vortioxetine has been shown to have fewer incidences of sleep-related adverse events reported in depressed patients. In a study comparing vortioxetine and paroxetine in healthy subjects, vortioxetine affected rapid eye movement (REM) sleep differently than paroxetine. Specifically, vortioxetine yielded normal sleep-wake rhythms while paroxetine continued to suppress REM sleep. This difference is thought to be due to vortioxetine's 5-HT3 receptor antagonism.

Vortioxetine has a less intense REM-suppressing effect than paroxetine

Vortioxetine (VOR) is a multimodal serotoninergic antidepressant that blocks serotonin transporter (SERT), 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, and 5-HT1A receptor agonist. It has been shown to have fewer incidences of sleep-related adverse events reported in depressed patients. In a comparative EEG study in rats, VOR was found to have a less intense REM-suppressing effect than paroxetine. This difference in REM suppression between the two antidepressants is likely due to VOR's 5-HT3 receptor antagonism.

In a study on healthy men, VOR was found to have a less intense REM-suppressing effect than paroxetine. The study also found that VOR had fewer effects on sleep fragmentation than paroxetine. Another study on adolescents with major depressive disorder found that VOR treatment resulted in higher REM latency and reduced REM sleep percentage. This indicates a potential dose-dependent REM-suppressing effect of VOR.

Vortioxetine has fewer effects on sleep architecture than paroxetine

Vortioxetine is a multimodal antidepressant that acts through serotonin (5-HT) transporter (SERT) inhibition, 5-HT3, 5-HT7 and 5-HT1D receptor antagonism, 5-HT1B receptor partial agonism, and 5-HT1A receptor agonism. It has been found to have fewer incidences of sleep-related adverse events reported in depressed patients.

A study comparing vortioxetine and paroxetine, another antidepressant, found that vortioxetine impacted the sleep architecture much less than paroxetine, particularly on measures of REM sleep and NREM to wake transitions, which are considered as measures of sleep fragmentation.

The study found that vortioxetine, at a given SERT occupancy, seemed to affect REM sleep differently than paroxetine. This difference is likely due to vortioxetine's 5-HT3 receptor antagonistic properties, which may lessen its effect on REM sleep.

Frequently asked questions